Form 4: Natera Executive Solomon Moshkevich Sells Shares Under 10b5-1 Trading Plan

Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a total of 80,000 shares of common stock on April 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., reported the sale of company stock on April 16, 2024.
• A total of 80,000 shares of common stock were sold in two transactions.
• The first transaction involved the sale of 26,511 shares at a weighted average price of $90.3369 per share.
• The second transaction involved the sale of 53,489 shares at a weighted average price of $91.0604 per share.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
• Following the reported transactions, Moshkevich directly owns 117,560 shares of Natera, Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting insider trading activity. The sentiment is neutral as it simply reports facts without expressing any opinion or forward-looking statements.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 plan suggests the sales were pre-planned and not based on current inside information. Investors often monitor insider transactions for signals about a company's prospects, but sales under a 10b5-1 plan are generally viewed as less informative.

Stakeholder Impact

• The stock sale by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates